IMS 2022 Express MRD-Driven Instructive Value for Discontinuation of Maintenance Therapy in Multiple Myeloma

This year's IMS Annual Meeting reported interim results from a phase II study evaluating MRD-negative status after discontinuation of maintenance therapy in patients who had been in persistent MRD-negative remission for >3 years

From February 2020 to July 31, 2022, a total of 23 patients (15 in Phase 1; 8 in Phase 2) were enrolled

In Phase 1, 13/15 (83%) patients remained MRD-negative 12 months after discontinuation of maintenance therapy

Preliminary results from Phase 1 demonstrate the feasibility of discontinuing maintenance therapy in persistently MRD-negative patients (>3 years)

Some researchers have also explored whether persistent MRD negativity can be used as an indicator of discontinuation of maintenance therapy in NDMM patients

Overall, 151 patients received induction therapy with a proteasome inhibitor-containing regimen and received HDM/ASCT

Our findings suggest that persistent MRD negativity after ASCT may be a safe and precise indicator of discontinuation of maintenance therapy

Reference source:

1.
Neha Korde, et al.
2022IMS.
Abstract#P-046.

2.
Panagiotis Malandrakis, et al.
2022IMS.
Abstract#P-051.

Click "Read the original text" to see more content